What Is Retatrutide? A Comprehensive Overview of LY3437943

Introduction

Retatrutide, known by its development code LY3437943, is an investigational peptide drug that marks a new step in metabolic medicine. Developed by Eli Lilly and Company, retatrutide is the first molecule in clinical development to simultaneously activate three metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This triple receptor agonism sets retatrutide apart from approved therapies, and striking Phase 2 results have drawn a lot of scientific interest.

Retatrutide reflects a wider shift in metabolic drugs. Over the past two decades, the field has moved from single-target approaches, such as GLP-1 receptor agonists like semaglutide and liraglutide, to multi-target strategies. Tirzepatide, also from Eli Lilly, showed what dual GIP/GLP-1 receptor agonism can do and received FDA approval for type 2 diabetes (as Mounjaro) and obesity (as Zepbound). Retatrutide takes the next logical step by adding glucagon receptor activation to the existing dual agonist framework.

Development Code and Nomenclature

Retatrutide carries the Eli Lilly development code LY3437943. The compound received its International Nonproprietary Name (INN) of “retatrutide” from the World Health Organization, following the naming convention for incretin-based peptides. The “-trutide” suffix indicates its membership in the class of multi-receptor agonist peptides related to the GIP/GLP-1/glucagon hormone family, similar to how tirzepatide’s “-tide” suffix reflects its peptide nature.

Retatrutide does not yet have a brand name, because no regulatory agency has authorized it for sale. References to retatrutide in the scientific literature may use either the INN or the LY3437943 designation, depending on the publication date and context.

The Triple Agonist Concept

What is new about retatrutide is that it acts on three receptor systems at once, each with its own effects:

GIP Receptor Agonism

GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone that enhances glucose-dependent insulin secretion and has emerging roles in fat tissue regulation and central appetite control. Retatrutide is most potent at the GIP receptor. That matters because GIP receptor agonism is now widely seen as a real contributor to metabolic improvement. The success of tirzepatide validated the principle that GIP agonism, when combined with GLP-1 receptor activation, can enhance weight loss and glycemic control beyond what GLP-1 agonism alone achieves.

GLP-1 Receptor Agonism

GLP-1 receptor activation is the best-proven mechanism in modern metabolic drugs. GLP-1 receptor agonists reduce appetite through central nervous system effects, improve glycemic control through glucose-dependent insulin secretion and glucagon suppression, and slow gastric emptying. In retatrutide, GLP-1 receptor agonism supplies the core metabolic benefits that have made this pathway the backbone of obesity and diabetes treatment.

Glucagon Receptor Agonism

Glucagon receptor agonism is what makes retatrutide new. Glucagon, traditionally viewed only as a counter-regulatory hormone that raises blood sugar, has significant effects on energy expenditure and hepatic lipid metabolism. Glucagon receptor activation increases resting energy expenditure and promotes fatty acid oxidation in the liver, contributing to calorie burning and liver fat reduction. There was a worry that glucagon’s glucose-raising effect would undo blood sugar control, but the GLP-1 and GIP receptor agonism working at the same time lowers glucose enough to offset it.

Why Retatrutide Matters

Weight Loss in Phase 3

The Phase 2 obesity trial, published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues, produced results that drew wide attention. In this 48-week trial of 338 adults with obesity, the highest-dose group (12 mg) achieved a mean body weight reduction of 24.2% from baseline. Two positive Phase 3 readouts have since beaten that figure by a wide margin: TRIUMPH-4 (December 2025) reported 28.7% mean weight loss at 12 mg over 68 weeks in 445 adults with obesity and knee osteoarthritis; TRIUMPH-1 (May 21, 2026) reported 28.3% mean weight loss at 12 mg over 80 weeks in 2,339 adults with obesity (no diabetes), with 45.3% of 12 mg participants achieving ≥30% weight loss and the 104-week extension reaching 30.3% in the BMI ≥35 subgroup. Together these are the largest mean weight reductions reported for any pharmacological agent in Phase 3 trials.

Blood Sugar Control

In the Phase 2 type 2 diabetes trial, published in The Lancet in 2023 by Rosenstock and colleagues, retatrutide lowered HbA1c by up to 2.02 percentage points. Most participants in the higher-dose groups reached HbA1c below 7.0%, and a sizable share got below 5.7%, the non-diabetic range. These results suggest retatrutide controls blood sugar as well as or better than existing therapies.

Liver Fat Reduction

One of the most striking secondary findings was a large drop in liver fat. In the obesity trial, participants in the highest-dose group experienced an average relative reduction in liver fat of approximately 82% from baseline. Given the growing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), this liver effect, likely driven by the glucagon receptor component, could be a significant benefit.

Metabolic Breadth

Beyond weight and glucose, retatrutide demonstrated improvements across a range of cardiometabolic parameters, including reductions in triglycerides, improvements in blood pressure, and favorable changes in waist circumference and body composition. The range of metabolic effects in Phase 2 suggests triple agonism tackles the many sides of metabolic disease more fully than single- or dual-target approaches.

Molecular Design

Retatrutide is a 39-amino-acid peptide that was engineered by Eli Lilly researchers to achieve balanced activity across all three target receptors. The molecule is based on a modified GIP peptide backbone, with specific amino acid substitutions and modifications to confer GLP-1 and glucagon receptor activity. A C20 fatty diacid moiety is conjugated to the peptide via a linker, facilitating binding to serum albumin. This albumin binding extends the molecule’s circulatory half-life to approximately six days, enabling once-weekly subcutaneous administration.

Retatrutide’s design builds on the evolutionary relationship among the GIP, GLP-1 and glucagon peptide families, all of which belong to the glucagon superfamily and share significant sequence homology. This shared ancestry made it feasible, though technically challenging, to construct a single peptide that engages all three receptor types with therapeutically relevant potency.

Current Development Status

As of October 31, 2026, retatrutide has completed its pivotal Phase 3 program with five positive readouts: TRIUMPH-4 (December 2025), TRANSCEND-T2D-1 (March 2026, published in The Lancet in June), TRIUMPH-1 (May 21, 2026), and TRIUMPH-2 and TRIUMPH-3 (July 23, 2026). It is not approved anywhere. The programs:

• TRIUMPH-1 through TRIUMPH-4 plus TRIUMPH-Outcomes: Evaluating retatrutide for obesity and weight management across different comorbidity populations, plus a roughly 10,000-patient cardiovascular outcomes trial. All four numbered trials have reported; TRIUMPH-Outcomes is ongoing.
• TRANSCEND: Type 2 diabetes program. TRANSCEND-T2D-1 reported topline results on March 19, 2026 and was published in The Lancet on June 6, 2026: HbA1c reductions of 1.69-1.94 percentage points and weight loss of 11.5-15.3% across doses. TRANSCEND-T2D-2 (head-to-head vs semaglutide 2 mg) reported topline results on October 28, 2026: A1C −2.2 points at 12 mg vs −1.8, weight −20.9% vs −9.4% at 80 weeks.
• SYNERGY / MACELD: Evaluating retatrutide for MASLD/MASH with liver outcomes endpoints.

Eli Lilly plans to file for FDA approval no later than the first quarter of 2027 (its most recent statement, October 8, 2026), which on our estimate points to a potential FDA decision in late 2027 with Priority Review or around the first quarter of 2028 under standard review. On October 2, 2026 the FDA ruled that retatrutide is a drug, not a biologic, so the application must be a New Drug Application (NDA); Lilly disputes the FDA ruling in court and has not said which pathway it will use.

How It Compares With Other Treatments

Retatrutide is arriving in a fast-moving field. GLP-1 receptor agonists have been a huge commercial and clinical success, with semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) transforming the treatment of obesity and diabetes. However, several unmet needs remain:

• Greater magnitude of weight loss: While current therapies produce clinically meaningful weight loss, many patients do not achieve the degree of weight reduction associated with sustained metabolic health improvement.
• Liver disease treatment: No pharmacological therapy is broadly approved for MASLD, and the liver fat reduction observed with retatrutide’s glucagon component may address this gap.
• Broader metabolic improvement: The multifactorial nature of metabolic syndrome suggests that multi-target approaches may provide broader benefits than single-receptor therapies.

Safety Considerations

Phase 2 showed that retatrutide’s safety profile is broadly in line with the known effects of incretin-based drugs. Gastrointestinal adverse events, including nausea, diarrhea, vomiting, and constipation, were the most commonly reported side effects and were predominantly mild to moderate in severity. Most gastrointestinal events occurred during dose-escalation periods and diminished over time. Treatment discontinuation rates due to adverse events were dose-dependent but remained within the range observed for other agents in this class.

No unexpected safety signals came out of the Phase 2 program. But the fairly small sample sizes of Phase 2 trials limit the ability to detect uncommon adverse events, and the larger Phase 3 TRIUMPH trials have since identified a new signal, dysesthesia (abnormal skin sensations), reported in 6.4% to 20.9% of participants at 12 mg across the obesity trials.

Looking Ahead

Retatrutide is a real step forward for metabolic drugs. Its triple receptor mechanism, record Phase 2 weight loss and broad metabolic effects have made it one of the most closely watched investigational compounds in endocrinology and obesity medicine. The Phase 3 TRIUMPH results reported so far have confirmed and extended the Phase 2 findings; the FDA’s review of Lilly’s planned application will determine whether that benefit profile is suitable for approval and widespread clinical use.

Longer-term questions remain open, including cardiovascular outcomes (TRIUMPH-Outcomes) and the head-to-head comparison with tirzepatide (TRIUMPH-5).